Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $1.88M rose 61.5% year over year, behind the +125.2% change in trailing-twelve-month research & development. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.
Context
- Research & development amounted to 9.7% of revenue in FY2025, up 1.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +61.5% toward the trailing-twelve-month pace of +125.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.77M USD
- Year-over-year change
- +138.6%
- 4-year CAGR
- +5.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.77M | +138.6% |
| FY2024 | 2024-12-31 | 3.26M | -2.0% |
| FY2023 | 2023-12-31 | 3.32M | -16.9% |
| FY2022 | 2022-12-31 | 4M | -35.9% |
| FY2021 | 2021-12-31 | 6.24M | — |
Research & Development vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 research & development of $8.48M is the 9th highest of the 10 companies compared; the peer median is $104.71M.
- Its year-over-year change of +125.2% is the highest of 10, against a peer median of +12.5%.
- Research & development amounts to 9.8% of revenue for ETON, versus a peer median of 37.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Sep 2026 | $245.55M | +16.8% | -3.2% | 37.7% | |
| LTM Mar 2026 | $152.7M | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $104.71M | +22.1% | +23.1% | 28.3% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| LTM Mar 2026 | $8.48M | +125.2% | +24.8% | 9.8% | |
| LTM Mar 2026 | $205K | -48.5% | -58.6% | 0.4% | |
| Peer median (excluding ETON) | $104.71M | +12.5% | +3.2% | 37.7% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.